ArticleFrontiers in bioengineering and biotechnology2020
A Combinational Strategy for Effective Heterologous Production of Functional Human Lysozyme in
Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- Microbial Production of Alternative Proteins for Food Applications: Advances, Industrial Challenges, and Regulatory Status.Comprehensive reviews in food science and food safety · 2026Review
- Special Milk and Synthetic Biology: A Dual-Perspective Review of Ingredient Substitutions in Breast-Milk-Simulated Infant Formula.Comprehensive reviews in food science and food safety · 2026Review
- Lysozyme as a natural feed additive in poultry and rabbit production: implications for growth, health and sustainability - a review.Tropical animal health and production · 2026Review
- Effect of lysozyme supplementation on growth performance, immune status, antioxidant function and intestinal microbiota in broilers.Poultry science · 2025Article
- The Fusion GenePlants (Basel, Switzerland) · 2025Article
- Characterizing heterologous protein burden in Komagataella phaffii.FEMS yeast research · 2025Article
- Cytokinetic engineering enhances the secretory production of recombinant human lysozyme in Komagataella phaffii.Microbial cell factories · 2024Article
- Effect of dietary supplementation with recombinant human lysozyme on growth performance, antioxidative characteristics, and intestinal health in broiler chickens.Journal of animal science · 2024Article
- Genomic insights into the phylogeny and biomass-degrading enzymes of rumen ciliates.The ISME journal · 2022Article
- Pathway engineering facilitates efficient protein expression in Pichia pastoris.Applied microbiology and biotechnology · 2022Review
- Recombinant expression of hen egg white lysozyme with the assistance of xylanase fusion partner inBioengineered · 2022Article
- Advances in Cell Engineering of theMetabolites · 2022Review
- Burden Imposed by Heterologous Protein Production in Two Major Industrial Yeast Cell Factories: Identifying Sources and Mitigation Strategies.Frontiers in fungal biology · 2022Review
- Engineering of the unfolded protein response pathway in Pichia pastoris: enhancing production of secreted recombinant proteins.Applied microbiology and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human lysozyme (hLYZ), known for its bacteriolytic activity, is widely applied in the food and pharmaceutical industries as an antimicrobial agent. However, its extensive application was limited by its low large-scale production efficiency. In this study, a combinational method of integrating codon optimization, multiple gene copies, and ER molecular chaperone co-expression was developed to improve the heterologous production of hLYZ in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.